Axsome Therapeutics Inc expected to post a loss of $1.33 a share - Earnings Preview

Axsome Therapeutics

02/08/2024 18:06

* Axsome Therapeutics Inc  AXSM.OQ   AXSM.O  is expected
to show a
rise in quarterly revenue when it reports  results on August 5
for the period ending June 30 2024
    * The New York City-based  company is expected to report a
88.9% increase in revenue to $86.922 million from $46.02 million
a year ago, according to the mean estimate from 16 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Axsome Therapeutics Inc
is for
a loss of $1.33 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 16 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Axsome
Therapeutics Inc is $117.50​, above​ its last closing price
of $86.01. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -1.22       -1.20      -1.44     Missed  -19.6
 Dec. 31 2024  -1.17       -1.17      -2.08     Missed  -77.6
 Sep. 30 2023  -1.22       -1.20      -1.32     Missed  -9.7​
 Jun. 30 2023  -1.22       -1.22      -1.54     Missed  -26
 ​​Mar.        -1.00       -1.04      -0.26     Beat    74.9
 31 2023                                                
 Dec. 31 2022  -1.09       -1.14      -1.41     Missed  -23.9​
 Sep. 30 2022  -1.06       -1.08      -1.07     Beat    0.9
 Jun. 30 2022  -1.25       -1.21      -1.06     Beat    12.3
 This summary was machine generated August 2 at 17:06 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)